Causes of end-stage renal disease (ESRD) in patients on hemodialysis in Al-GharbiyahGovernorate in Egypt

Abd El Raouf, Y. M^{*} and Alghazal, G^{*}

*Internal Medicine Department, Faculty of Medicine, Tanta University, Egypt. <u>masyasser@yahoo.com</u>

Abstract: Chronic kidney disease (CKD) is an increasing global burden regarding social, epidemiological and economic aspects. The burden is greater in the developing counties because of limited resources and poverty. In Egypt the problem is increasing and it represents one of the major health problems. One of the first steps of prevention of CKD and hence of ESRD is identification of the causes of this problem. The present study is an epidemiological study which carried out through questionnaire . Aiming to find out the causes of ESRD in Algharbiyah Governorate in Egypt. All governmental haemodialysis units in Al-Gharbiyah Governorate and private hemodialysis centers wereincluded in the study. 980 patients with ESRD on hemodialysis were included. A modified form of Egyptian society of nephrology Questionnaire was used. The mean age of patients was 52.27±12.91 years. Percentage of patients from rural areas and that from urban areas was (61.9% vs 39.1). All patients were under Hemodialysis 3 times per week, hypertension accounted for 31.8% of all causes of ESRD, diabetic nephropathy 22.9%. and Unknown cause 11.9, chronic pyelonephritis was responsible for 0.6% of ESRD cases, chronic glomerulonephritis represented 1.4% of all cases. While shistosomiasis was responsible for 0.9% of treated ESRD and Polycystic kidney disease accounted for 3.7% of all causes of ESRD. In conclusion: hypertensive nephropathy was the most common cause of ESRD in Al-Gharbiyah Governoratefollowed by diabetic nephropathy. [Abd El Raouf, Y. M and Alghazal, G. Causes of end-stage renal disease (ESRD) in patients on hemodialysis in Al-Gharbivah Governorate in Egypt. Life Sci J2015;12(8):45-55]. (ISSN:1097-8135). http://www.lifesciencesite.com. 8

Key words: Endstage renal disease, Diabetic nephropathy, Hypertension, Glomerulonephritis.

1. Introduction

CKD is either kidney damage or a decreased glomerular filtration rate (GFR) of less than 60 mL/min/ 1.73 m^2 for 3 or more months. Whatever the underlying etiology, once the loss of nephrons and reduction of functional renal mass reaches a certain point; the remaining nephrons begin a process of irreversible sclerosis that leads to a progressive decline in the GFR (**KDIGO Guideline, 2013**).

Pofessional guidelines classify the severity of CKD in five stages, with stage 1 being the mildest and usually causing few symptoms and stage 5 being a severe illness with poor life expectancy if untreated. Stage 5 CKD is often called end stage renal disease (National Kidney Foundation, 2002).

ESRD is the point of irreversible renal function deterioration beyond which life can no longer be sustained without treatment. Importantly, appropriate pre-ESRD care ensures that the patients are in the best overall condition when they start dialysis (Abboud and Henrich, 2010).

Chronic renal failure (CRF) is a debilitating condition responsible for high morbidity and mortality and is a financial burden on government and society because of its costs and the complexity of its treatment (Agarwal *et al.*, 2005).

Costs for dialysis and renal transplantation are still unaffordable for most patients with ESRD. Since the cost burden has significantly increased, nephrology services should be changed from curative medicine to preventive medicine(Soliman *et al.*,2012).

ESRD is associated with increased psychological distress and diminished quality of life (QoL) (Kimmel and Peterson, 2005). The high prevalence of CKD-has related morbidity with increased prevalence of anemia, acidosis and renal bone disease. Other possible associated comorbidities with CKD are heart failure, periodic hypoglycemia and obstructive sleep apnea (Gullion *et al.*, 2006).

ESRDhas significantly increased in developed and developing countries, diabetes mellitus is still the leading cause of ESRD in developed countries, also in these countries hypertension is an important cause (Kdoqi, 2007).

Polycystic kidney disease is another well-known cause of CKD (Alam and Perron, 2010). Chronic pyelonephritis, chronic glomerulonephrits and interstitial nephritis are currently the principal causes of CKD in developing countries reflecting the high prevalence of bacterial, viral and parasitic infection (Barsoum, 2002).

Overuse of common drugs such as aspirin, ibuprofen, and acetaminophen (paracetamol) can also cause chronic kidney damage(**Mihatsch** *et al.*(2006).

Unfortunately, no clear statistical data are available in Al-Gharbiyah Governorate regarding the causes of ESRD. Therefore, the present work will be directed to find out the most common Causes of ESRD in Al-Gharbiyah Governorate in trial to deal with these causes.

2.Patients and Methods

This study was conducted in governmental dialysis units and private hemodialysis centers in Al-Gharbiyah Governorate on 980 patients through a modified form of Egyptian society of nephrology Questionnaire. The questionnaire was filled by us depending on data obtained from physicians responsible for dialysis units, obtained from files and patients. A consent was taken from patients to use their data in a confidential manner.

Inclusion criteria

All governmental haemodialysis units in Al-Gharbiyah Governorate and private haemodialysis centers were included in the study. The Questionnaire used in this study is included in appendix 1.

Exclusion criteria

Patients refused to give consent and non motivated responsible physicians were excluded from the study.

3.Results:

As shown in tables 1& 2);we can see acomparison between all studied patients (980) as regard age, sex and weight, it shows no statistically significant difference in all (p>0.05). There is statistically significant difference in residency of patients as being those from rural areas (60.9%) more than those from urban areas (39.1%) (p=0.0001), regarding occupation more patients with ESRD on hemodialysis arejobless (64.1%) (p=0.0001), less in highly educated (11.9%) (p=0.0001), only 4.3% had +ve family history and regarding habits there are more in those without special habits(82.4%), (16.9%) are smoking and (0.6%) alcoholic (0.043). Also; baseline diseases at time of starting dialysis showed no LVF in (99.4%) of patients (p=0.001), COPD was absent in (97.9%) of patients (p=0.004), and hepatitis C viral infection was absent in (55%) of patients (p=0.0001).

As seen in table (3), there is significant difference in causes of ESRD detected among the studied patients among different dialysis units reflux regarding: nephropathy and chronic pyelonephritis, obstructive uropathy, gouty nephropathy, complication of pregnancy (eclampsia or pre-eclampsia), renal affection secondary to collagen disease and ESRD of unknown etiology, and the most common causes are hypertension (31.9%, and there was no significant difference among all dialysis units regarding this cause with P value=0.135), diabetic nephropathy (22.9%, and there was no significant difference among all dialysis units regarding this cause with P value=0.617), unknown cause (11.6%, and there was significant difference among all dialysis units regarding this cause with P value=0.0001) and obstructive uropathy (10.7%, and there was no

significant difference among all dialysis units regarding this cause with *P* value=0.707). Figure (1)

In table (4) we can find the causes of ESRD among the studied patients in Tanta (capital of the governorate) governmental dialysis units in Al-Gharbiyah Governorate being the most common causes are hypertension (35.3%, and there was significant difference among all dialysis units regarding this cause with P value=0.025), diabetic nephropathy (19.7, with P value=0.022 among all dialysis units), obstructive uropathy (11.2% and P)value among studied units was 0.742) and unknown causes (11.2% with P value=0.1 among all dialysis units). The causes of ESRD varied from a dialysis unit to another in Tanta city (total number=249). In Moubarra unit, diabetic nephropathy represents (39.4%) of the causes, hypertensive nephropathy (12.2%) and analgesic nephropathy (12.1%). In Mougamaa unit, hypertensive nephropathy represents (39.5%) of the causes, diabetic nephropathy (14%) and unknown cause (14%). In Minshawy unit, hypertensive nephropathy (28.6%), diabetic nephropathy (17.6%) and unknown cause (15.4%). In Tanta University unit, hypertensive nephropathy (46.3%), diabetic nephropathy (17.1%), obstructive uropathy (11%) and unknown cause (9.8%). Figure (2)

As shown in table (5), the most common causes of ESRD among the studied patients in El-Mahalla El-Kobra (second big city in the governorate) dialysis units (n=220) are as follows: diabetic nephropathy (24.5% with *P* value= 0.0001 among the studied dialysis units in El- Mahalla), hypertension (24.1% with P value= 0.027 among the studied dialysis units in El- Mahalla), unknown cause (12.7% and *P* value among studied units was 0.109)and obstructive uropathy (10% with P value= 0.048 among studied units). Figure (3)

Table (6) shows the duration of hemodialysis of the studied patients in governmental dialysis units in Al-Gharbiyah Governorate with mean duration of (4.25 ± 3.70) . The longest duration is in El Mahalla El Koubra units (6.38 ± 4.12) and the shortest is in Zafeta unit (2.96 ± 3.22), and the difference among studied units in the governorate was significant with P=0.001.

As it is clear from table (7), the health problems diagnosed among the studied patients in dialysis unitsare significantly different in all (ischemic heart disease P=0.004, peripheral vascular disease P=0.0001, hepatitis C virus P=0.0001 and renal osteodystrophy P=0.0001) except in malignancy (P>0.05).

We can see in table (8) that there is no significant difference in causes of ESRD in relation to area of residence as there is no significant difference between urban and rural areas (P>0.05).

				dialysis u	nits (n=	980)															
	Gove	rnmental	units (n=	=842)																	
Variables	Tanta (n=24	a units 19)	El-Ma El-Ko units (n=22)	ubra	Bass unit (n=3		EI-S: unit (n=5		Zeft: (n=3	a unit 8)	Kafr Zayat (n=11		Koto unit (n=5		Sam: unit (n=8	anoud 0)	Privat (MK) (n=13		Total (n=98		$\stackrel{\chi^2}{P}$
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
•Age (years): Range Mean±SD F value	14-91 53.16 1.053	±14.02	14-80 51.64±	-12.62	26-72 51.42	2 2±10.13	20-7 52.2	7 5±11.73	12-6 47.10	7 5±12.41	20-83 52.52±	12.72	23-78 51.86	8 5±13.25	20-75 52.79	5 9±12.29	20-80 52.94	⊧12.86	12-91 52.27	±12.91	
Р	0.394																				
•Sex: Males Females	149 100	59.8 40.2	118 102	53.6 46.4	21 15	58.3 41.7	31 20	60.8 39.2	25 13	65.8 34.2	74 43	63.2 36.8	29 22	56.9 43.1	56 24	70.0 30.0	92 46	66.7 33.3	595 385	60.7 39.3	10.771 0.215
•Residence: Urban Rural	112 137	45.0 55.0	117 103	53.2 46.8	18 18	50.0 50.0	20 31	39.2 60.8	11 27	28.9 71.1	41 76	35.0 65.0	7 44	13.7 86.3	4 76	5.0 95.0	53 85	38.4 61.6	383 597	39.1 60.9	79.084 0.0001*
•Occupation: Worker Employer Farmer No work	20 82 8 139	8.0 32.9 3.2 55.8	4 45 4 167	1.8 20.5 1.8 75.9	1 9 2 24	2.8 25.0 5.6 66.7	10 5 5 31	19.6 9.8 9.8 60.8	1 10 1 26	2.6 26.3 2.6 68.4	1 19 9 88	0.9 16.2 7.7 75.2	1 5 4 41	2.0 9.8 7.8 80.4	4 23 7 46	5.0 28.8 8.8 57.5	7 57 8 66	5.1 41.3 5.8 47.8	49 255 48 628	5.0 26.0 4.9 64.1	103.342 0.0001*
•Education: Not educated Basic educ. Secondary High educ.	102 26 77 44	41.0 10.4 30.9 17.7	46 45 108 21	20.9 20.5 49.1 9.5	16 7 10 3	44.4 19.4 27.8 8.3	31 6 14 3	60.8 11.8 25.5 2.0	15 6 14 3	39.5 15.8 36.8 7.9	25 32 54 6	21.4 27.4 46.2 5.1	20 11 19 1	39.2 21.6 37.3 2.0	38 14 24 4	47.5 17.5 30.0 5.0	51 6 51 30	37.0 4.3 37.0 21.7	344 153 370 113	35.1 15.6 37.8 11.5	121.576 0.0001*
•Habits: -ve Smoking Alcohol	189 58 2	75.9 23.3 0.8	187 32 1	85.0 14.5 0.5	32 4 0	88.9 11.1 0	39 12 0	76.5 23.5 0	34 4 0	89.5 10.5 0	94 20 3	80.3 17.1 2.6	41 10 0	80.4 19.6 0	68 12 0	85.0 15.0 0	124 14 0	89.9 10.1 0	808 166 6	82.4 16.9 0.6	26.883 0.043*
•Family history: -ve +ve	236 13	94.8 5.2	207 13	94.1 5.9	32 4	88.9 11.1	50 1	98.0 2.0	36 2	94.7 5.3	115 2	98.3 1.7	50 1	98.0 2.0	77 3	96.2 3.8	135 3	97.8 2.2	938 42	95.7 4.3	10.915 0.207

 Table (1): Demographic data of the studied patients: *Significant (P<0.05)</th>

Table (2): Body weight and history in disease of the studied patients (n=980).

		ed pati	ents in	dialy	sis uni	ts												-		
		ental u	nits															Tota	al	
	9)	Koubra	a units)	unit (n=3	5)	unit (n=5	1)	(n=3	8)	(n=11)	7)	unit (n=5	1)	unit (n=8))	(n=1.	38)	Ì	,	p^{χ^2}
n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
73.41		35-168 72.66±1	17.75													45-140 73.28±1	13.69			
	*																			
129 120	51.8 48.2	78 142	35.5 64.5	7 29	19.4 80.6	22 29	43.1 56.9	11 27	28.9 71.1	45 72	38.5 61.5	15 36	29.4 70.6	33 47	41.3 58.8	101 37	73.2 26.8	441 539	45.0 55.0	78.075 0.0001*
248 1	99.6 0.4	210 10	95.5 4.5	33 3	91.7 8.3	50 1	98.0 2.0	38 0	100 0	117 0	100 0	49 2	96.1 3.9	80 0	100 0	134 4	97.1 2.9	959 21	97.9 2.1	22.535 0.004*
244 5	98.0 2.0 0	220 0	100 0	35 0	97.2 0 2.8	51 0	100 0	38 0	100 0	117 0	100 0	51 0	100 0	80 0	100 0	138 0	100 0	974 5	90.4 0.5 0 1	40.993 0.001*
	(n=9 Gov (n=8 Tanta (n=24 n 38-134 73.415 3.505 0.0014 129 120 248 1 244	(n=980) Governmedia Tanta units (n=249) Tanta units (n=249) anta units (n=244 38-134 73.41±13.36 3.505 0.001* 0.001* 129 51.8 48.2 248 99.6 0.4 244 98.0 2.0	(n=980) Governmental un (n=842) Tanta units (n=249) Tanta units (n=240) Tanta units (n=240) Tanta units (n=240) Tanta units (n=240) n % Tanta units (n=240) n % 3.505 3.5.168 78.122 129 51.8 78.122 248 99.6 210 1 0.4 10 244 98.0 220 0	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $

*Significant (P<0.05)

NB. EF was recorded among two patients in Tanta Units HCV=Hepatitis C virus infection, COPD=Chronic obstructive pulmonary disease, LVF=Left ventricular failure

			<u> </u>	in dialys										0		1				/		
		ernment			is ante	(n 900)													1			
Variables	Tant units (n=2	ta s	El- Mah	alla oubra	Bass unit (n=3		EI-S unit (n=5		Zef (n=	ta unit 38)		r EL- ut Unit 17)	Koto unit (n=5		Sam unit (n=8	anoud 0)	Priv unit unit) (n=1	(MK	Total (n=98		χ²	Р
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
•Reflux nephropathy and chronic pyelonephritis	12	4.8	18	8.2	0	0	2	3.9	6	15.8	13	11.1	1	2.0	4	5.0	9	6.5	65	6.6	16.416	0.037*
•Chronic glomerulonephritis	3	1.2	6	2.7	0	0	1	2.0	0	0	2	1.7	0	0	0	0	2	1.4	14	1.4	5.863	0.663
 Diabetic nephropathy 	49	19.7	54	24.5	7	19.4	9	17.6	9	23.7	35	29.9	12	23.5	19	23.8	30	21.7	224	22.9	6.272	0.617
 Hypertensive dis. of kidney 	88	35.3	53	24.1	10	27.8	19	37.3	8	21.1	40	34.2	16	31.4	28	35.0	50	36.2	312	31.8	12.392	0.135
 Obstructive uropathy due to shistosomiasis 	2	0.8	4	1.8	1	2.8	0	0	0	0	1	0.9	0	0	0	0	1	0.7	9	0.9	5.463	0.707
 Obstructive uropathy 	28	11.2	22	10.0	3	8.3	3	5.9	5	13.2	9	7.7	4	7.8	19	23.8	12	8.7	105	10.7	18.241	0.019*
 Gouty nephropathy 	1	0.4	0	0	2	5.6	1	2.0	0	0	1	0.9	0	0	0	0	0	0	5	0.5	23.202	0.003*
•Complication of pregnancy (eclampsia or pre- eclampsia)	2	0.8	3	1.4	6	16.7	0	0	2	5.3	1	0.9	0	0	0	0	5	3.6	19	1.9	51.735	0.0001*
Polycystic kidney	8	3.2	12	5.5	0	0	1	2.0	1	2.6	4	3.4	2	3.9	5	6.3	3	2.2	36	3.7	6.442	0.598
•Other hereditary dis.	3	1.2	7	3.2	1	2.8	0	0	0	0	2	1.7	3	5.9	0	0	1	0.7	17	1.7	12.299	0.138
 Lupus nephritis 	7	2.8	1	0.5	0	0	1	2.0	0	0	2	1.7	0	0	1	1.3	0	0	12	1.2	9.979	0.267
 Renal affection secondary to collagen dis. 	1	0.4	0	0	2	5.6	1	2.0	0	0	0	0	0	0	0	0	1	0.7	5	0.5	22.945	0.003*
•Analgesic nephropathy	13	5.2	8	3.6	0	0	1	2.0	0	0	3	2.6	1	2.0	0	0	2	1.4	28	2.9	11.340	0.183
 Renal amyloidosis 	1	0.4	1	0.5	0	0	0	0	0	0	2	1.7	1	2.0	0	0	1	0.7	6	0.6	5.402	0.714
•Other cause	3	1.2	3	1.4	0	0	0	0	0	0	2	1.7	0	0	0	0	1	0.7	9	0.9	3.938	0.863
 Renal failure of unknown etiology 	28	11.2	28	12.7	4	11.1	12	23.5	7	18.4	0	0	11	21.6	4	5.0	20	14.5	114	11.6	33.850	0.0001*

Table (3): Etiological diseases of ESRD detected among the studied patients (n=980).

*Significant (P<0.05)

Table (4): Causes of ESRD	detected among the studied	patients in Tanta governmental	dialysis units (n=249).

	The st	udied pati	ents in T	anta gover	mmenta	l dialysis	units (n=2	49)				
Variables	Moub unit (n=33)		Moug unit (n=43		Minsl unit (n=91		Tanta unit (n=82)	university	Tota (n=2	249)	χ²	Р
	n	%	n	%	n	%	n	%	n	%		
 Reflux nephropathy and chronic pyelonephritis 	2	6.1	2	4.7	6	6.6	2	2.4	12	4.8	1.751	0.626
 Chronic glomerulonephritis 	0	0	1	2.3	1	1.1	1	1.2	3	1.2	0.865	0.834
 Diabetic nephropathy 	13	39.4	6	14.0	16	17.6	14	17.1	49	19.7	9.612	0.022*
 Hypertensive dis. of kidney 	7	21.2	17	39.5	26	28.6	38	46.3	88	35.3	9.381	0.025*
 Obstructive uropathy due to shistosomiasis 	0	0	1	2.3	1	1.1	0	0	2	0.8	2.282	0.516
 Obstructive uropathy 	2	6.1	5	11.6	12	13.2	9	11.0	28	11.2	1.245	0.742
 Gouty nephropathy 	0	0	0	0	1	1.1	0	0	1	0.4	1.743	0.627
 Complication of pregnancy (eclampsia or pre-eclampsia) 	0	0	0	0	1	1.1	1	1.2	2	0.8	0.894	0.827
 Polycystic kidney 	3	9.1	2	4.7	0	0	3	3.7	8	3.2	7.026	0.071
•Other hereditary dis.	0	0	1	2.3	0	0	2	2.4	3	1.2	3.015	0.389
•Lupus nephritis	1	3.0	0	0	3	3.3	3	3.7	7	2.8	1.544	0.672
 Renal affection secondary to collagen dis. 	0	0	0	0	1	1.1	0	0	1	0.4	1.743	0.627
Analgesic nephropathy	4	12.1	2	4.7	7	7.7	0	0	13	5.2	8.844	0.031*
 Renal amyloidosis 	1	3.0	0	0	0	0	0	0	1	0.4	6.572	0.087
•Other cause	0	0	0	0	2	2.2	1	1.2	3	1.2	1.681	0.641
 Renal failure of unknown etiology 	0	0	6	14.0	14	15.4	8	9.8	28	11.2	6.242	0.100

*Significant (P<0.05)

	The stud	lied patients i	n El-Mahall	a dialysis units ((n=220)			
Variables	Moubar (n=59)	rha unit	General (n=161)	hospital unit	Total (n=22	0)	χ^2	Р
	n	%	n	%	n	%		
•Reflux nephropathy and chronic pyelonephritis	0	0	18	11.2	18	8.2	7.184	0.007*
Chronic glomerulonephritis	0	0	6	3.7	6	2.7	2.260	0.133
 Diabetic nephropathy 	39	66.1	15	9.3	54	24.5	75.174	0.0001*
Hypertensive dis. of kidney	8	13.6	45	28.0	53	24.1	4.890	0.027*
 Obstructive uropathy due to shistosomiasis 	4	6.8	0	0	4	1.8	11.117	0.001*
 Obstructive uropathy 	2	3.4	20	12.4	22	10.0	3.914	0.048*
 Complication of pregnancy (eclampsia or pre- eclampsia) 	0	0	3	1.9	3	1.4	1.115	0.291
Polycystic kidney	1	1.7	11	6.8	12	5.5	2.210	0.137
•Other hereditary dis.	0	0	7	4.3	7	3.2	2.650	0.104
Lupus nephritis	0	0	1	0.6	1	0.5	0.368	0.544
 Analgesic nephropathy 	0	0	8	5.0	8	3.6	3.042	0.081
Renal amyloidosis	1	1.7	0	0	1	0.5	2.741	0.098
•Other cause	0	0	3	1.9	3	1.4	1.115	0.291
Renal failure of unknown etiology	4	6.8	24	14.9	28	12.7	2.568	0.109

Table (5): Causes of ESRD detected among the studied patients in El-Mahalla dialysis units

*Significant (P<0.05)

Table (6):Duration of hemodialysis of the studied patients in governmental dialysis units in Al Gharbiyha province

	The studied	patients in dial	ysis units (n=9	980)						
	Governmen	tal units (n=842	2)						Private	
Variables	Tanta units (n=249)	El-Mahalla El-Koubra units (n=220)	Bassioun unit (n=36)	El-Santa unit (n=51)	Zefta unit (n=38)	Kafr EL- Zayat Unit (n=117)	Kotour unit (n=51)	Samanoud unit (n=80)	unit (MK unit) (n=138)	Total (n=980)
 Duration of 										
hemodialysis										
(years):										
Range	2 w18 y.	2 w20 y.	4 m15 y.	4 m9 y.	2 w15 y.	2 w16 y.	2 w20 y.	2 w20 y.	2 w16 y.	2 w20 y.
Mean±SD	4.00 ± 3.45	6.38±4.12	4.04±3.81	4.13±2.16	2.96±3.22	3.78±3.42	3.94±4.31	3.43±3.01	3.33±2.87	4.25±3.70
χ^2 value	140.031									
Р Р	0.001*									

*Significant (P<0.05)

Table (7): Show the health problems diagnosed among the studied patients in dialysis units

	The s	tudied	patients	in dialy	ysis units (n=	=980)																
	Gove	rnment	al units	(n=842)																	
riables	Tant: units (n=24		El- Mah El- Koul units (n=2)	ora	Bassioun (n=36)	unit	El-Sar unit (n=51)		Zeft unit (n=5		Kaf Zay Unit (n=1	t	Kot unit (n=:		San d ui (n=		uni uni	vate t (MK t) 138)	Tota (n=9		χ²	Р
Va	n	%	Ν	%	n	%	Ν	%	n	%	N	%	n	%	n	%	n	%	n	%		
 Ischemic heart disease 	35	14. 1	23	10. 5	6	16.7	7	13. 7	5	13. 2	5	4.3	1	2.0	1 5	18. 8	2 6	18. 8	12 3	12. 6	22.31 7	0.004*
 Peripheral vascular disease 	16	6.4	0	0	0	0	0	0	0	0	1	0.9	0	0	0	0	0	0	17	1.7	43.51 5	0.0001 *
 Malignancy 	2	0.8	2	0.9	0	0	0	0	1	2.6	2	1.7	1	2.0	1	1.3	0	0	9	0.9	4.858	0.773
•HCV	11 7	47. 0	14 5	65. 9	27	75.0	2 9	56. 9	2 7	71. 1	7 1	60. 7	3 4	66. 7	4 9	61. 3	4 0	29. 0	53 9	55. 0	70.21 1	0.0001 *
 Renal osteodystrop hy 	21	8.4	26	11. 8	5	13.9	1	2.0	2	5.3	0	0	1	2.0	1	1.3	0	0	57	5.8	43.44 5	0.0001 *

*Significant (P<0.05)

	Residence of	the studied pati	ients in dialysis	s units (n=980)		
Variables	Urban (n=38	3)	Rural (n=59'	7)	χ^2	Р
	Ν	%	n	%		
Reflux nephropathy & pyelonephritis	24	6.3	41	6.9	0.136	0.712
 Chronic glomerulonephritis 	7	1.8	7	1.2	0.711	0.399
Diabetic nephropathy	98	25.6	126	21.1	2.658	0.103
Hyperensive dis. of kidney	123	32.1	189	31.7	0.022	0.881
 Obstructive uropathydut to schistomasis 	2	0.5	7	1.2	1.084	0.298
 Obstructive uropathy 	34	8.9	71	11.9	2.218	0.136
Gouty nephropathy	1	0.3	4	0.7	0.769	0.381
•Complication of pregnancy (eclampsia or pre-eclampsia)	8	2.1	11	1.8	0.074	0.785
Polycystic kidney	17	4.4	19	3.2	1.040	0.308
•Other hereditary dis.	6	1.6	11	1.8	0.104	0.747
•Lupus nephritis	5	1.3	7	1.2	0.034	0.853
Renal affection secondary to collagen dis.	2	0.5	3	0.5	0.002	0.966
•Analgesic nephropathy	11	2.9	17	2.8	0.001	0.982
Renal amyloidosis	3	0.8	3	0.5	0.302	0.582
•Other cause	3	0.8	6	1.0	0.126	0.723
Renal failure of unknown etiology	39	10.2	75	12.6	1.286	0.257

Table (8): show that there are no significant difference in causes of ESRD detected among the studied patients in relation to their residence (n=980).

*Significant (P<0.05)




Figure (1): Causes of ESRD among the studied patients (n=980).




Figure (2): shows the causes of ESRD among Tanta governmental dialysis units as in Moubarra unit diabetic nephropathy (39.4%), hypertensive nephropathy (12.2%) and analgesic nephropathy (12.1%). In Mougamaa unit, hypertensive nephropathy (39.5%), diabetic nephropathy (14%) and unknown cause (14%). In Minshawy unit, hypertensive nephropathy (28.6%), diabetic nephropathy (17.6%) and unknown cause (15.4%). In Tanta University unit hypertensive nephropathy (46.3%), diabetic nephropathy (17.1%), obstructive uropathy (11%) and unknown cause (9.8%). (n=249).




Figure (3): Shows the causes of ESRD among the studied patients in El-Mahalla El-Kobra dialysis units (n=220): diabetic nephropathy (24.5%), hypertension (24.1%), unknown (12.7%) and obstructive uropathy (10%) (n=220).

4.Discussion

Chronic renal disease is a public health problem with epidemiological, social, and economic

implications. In developed countries there is electronic data registry which allows easy statistical analysis and determination of the size of the problem for future

plans. In developing countries there is no data registry and only few data were available about epidemiology of dialysis patients.

The results of the present study showed that the prevalence of treated ESRD in males was almost twice that of females (60.7% vs 39.3%). This male predominance among the ESRD population, almost a global phenomenon, is poorly explained, with males constituting 56%according to US (Uinted States) Renal Data System (USRDS), 2012 in the US, 60% in the UK (United Kingdom) Renal Registry, 2010 and 54.5% in the KSA (Kingdom of Saudi Arabia) (Al-Sayyari and Shaheen, 2011).

In the present study the mean age was 52.27 ± 12.91 years. Afifi, 2008, reported that mean age in Egypt increased from 45.6 years in 1996 to 49.8 years in 2008. Increasing mean age of ESRD patients reflects the improvement of health care however we still away from developed countries as mean age in United State was 61.1 years according to USRDS, 2012 and median age in United Kingdom (UK) was 65.9 years according to Steenkamp *et al.*, 2011.

Most of the patientscome from rural areas than from urban areas (61.9% vs. 39.1% respectively). All were dialyzed three times per week with average (4 hours) as a duration of each dialysis session, among the 980 patients, 11.5% were highly educated, 35.1% not educated, and basic and secondary education represented 15.5%, 37.8% of total number of patients respectively. There is high incidence of ESRD in low educated and low incidence in highly educated patients. This can be explained with good sanitation and proper health care in the highly educated group of patients. The main duration of dialysis was 4.25±3.70 in years. The longest main duration of dialysis is 6.38±4.12 in El-Mahalla El-Koubra general hospital unit, this indicates good care of patients leading to good survival rate.

Etiology of treated ESRD in the current study was hypertension in about 31.8% of the causes of treated ESRD in the area of Al-Gharbiyah Governorate. In Sudan, **El-Amin** *et al.*, **2010** reported that hypertension was responsible for about 26% of the causes of treated ESRD. Similarly, hypertension was the cause of treated ESRD in 28% of ESRD cases in the US according to **USRDS, 2012**. In Iran, **Malekmakan** *et al.*, **2009**, found that, the most common cause of treated ESRD among HD patients was hypertension (30.5%), but this is likely an overestimate as the diagnosis of hypertensive nephrosclerosis is difficult to ascertain even in patients with long-standing hypertension. Such patients may have had secondary hypertension due to undiagnosed kidney disease.

Naicker, 2009 stated that hypertension was the cause of kidney failure in 21% of patients on renal replacement therapy (RRT) in the South African

registry. Hypertension is responsible for 20% of the causes of treated ESRD in El-Minia Governorate in Egypt, and in El- Menofia governorate, Egypt, the main known cause of ESRD was hypertension (34.8 %) followed by diabetes (16.6 %). (El-Minshawy, 2011). A similarly wide variation is noted in the reported rates of hypertension as the primary cause of ESRD patients in the US and UK (28% and 5.8%, respectively), this according to UK Renal Registry, 2010 and USRDS, 2012.

The variation in the reported rates of hypertensive nephrosclerosis likely results from the different definitions of these conditions rather than a true variation of prevalence. Among the reasons for this difference are the delay in detecting renal disease and the failure to institute controlling and preventive measures in patients with progressive renal failure, both of which result in faster deterioration of renal function and progression to ESRD, and because of that chronic renal failure patients are referred late to nephrologists.

Diabetic nephropathy was responsible for 22.9% of causes of ESRD in the current study, while Naicker, 2009, found that the prevalence of diabetic nephropathy is estimated to be 14-16% in South Africa. 23.8% in Zambia, 9% in Sudan, and 6.1% in Ethiopia. In Egypt, Afifi, 2008, reported that the prevalence of diabetic nephropathy among ESRD patients is 14.5% .The reasons for this increase is the prevalence of diabetic nephropathy (DN) in the population, is mainly due to improvement in survival of patients with type 2 diabetes. However, in China, Yao et al., 2009, found that the incidence of diabetic nephropathy increased from 9.9% in 2000 to 17.2% in 2005. In France, Couchoud et al., 2009, reported that during the vear 2007, 39% of patients with ESRD on HD were diabetics. Also, Pérez-Oliva, 2009, reported that the main cause of ESRD in Cuba in 2006 was diabetes mellitus. Udayaraj et al., 2009, stated that in England, diabetes mellitus was seen in 28.9% of patients on RRT while Malekmakan et al., 2009, reported that diabetes mellitus constitutes 30.1% of the causes of chronic renal failure in Iranian HD patients. In Qatar, diabetic nephropathy was the commonest cause of ESRD (48%) (Shigidi et al., 2009), and 44% in the US according to **USRDS**, 2012.

Afifi, 2008, found that in Egypt the prevalence of DN as a cause of ESRD was increased from 8.9 % in 1997 to 13.5 % in 2008 and still accounting for the 2^{nd} cause of ESRD as hypertension is the main cause with 36.6%, while in Kuwait it was 25% constituting 2^{nd} cause after glomerlulonephritis which accounts 32 % (El-Reshaid *et al.*, 2005), and in Saudi Arabia DN accounts for 25.2 % as 2^{nd} cause following hypertension with 30.4 % as reported by Shaheen and Al-Khader, 2005.

In the present study the unknown cause of ESRD accounts for 11.9% of all causes of ESRD. It was estimated to be 27 % inMinia governorate, 18.1 % in Cairo governorate (Elminshawy, 2011), and allover Egypt it was estimated to be 15.2 % (Afifi, 2008). In Sudan, El-Amin *et al.*, 2010, found that more than 40% of the surveyed patients had no identified cause for their renal impairment. Uncertain etiology of ESRD was estimated to be 14.4 % in Iran by Malekmakan *et al.*, 2009, 14% in Qatar by Shigidi *et al.*, 2009, and reported to be 19.9 % in Saudi Arabia by Shaheen Shaheen and Al-Khader, 2005. And the unknown etiology of ESRD in the US is only 5% according to USRDS, 2012.

This difference may be attributed to environmental factors. The demonstrated great difference reflects the poor health care system in developing countries.

Elminshawy, 2011, reported thatin some Egyptian governorates like Cairo the main cause of ESRD was hypertension with 29.7% followed by DN with 12.5 %, in Canal governorates hypertension was the main cause of ESRD with 27.3 % followed by DN with 10.7%, and in Minia governorate the main cause was also hypertension with 20 % followed by DN 8%.

Chronic glomreulonephritis (GN) was 1.4% in our study. In Sudan, **El-Amin** *et al.*, **2010**, reported that GN was the reported cause of treated ESRD in 5.5% of the patients, 3.9% in the US (**USRDS**, **2012**) while in Kuwait it for accounts 32 % of causes of ESRD according to **El-Reshaid** *et al.*, **2005**. In El-Minia Governorate it accounts for 11% of causes of ESRD, 15.8% inCairo Governorat, and 2.5% in Canal Governorates (**Elminshawy**, **2011**).

In present study, schistosomiasis was responsible for about 0.9% of the etiology of ESRD treated with HD. In Egypt; schistosomiasis responsible for 1.5-6.6% of the treated ESRD (Afify, 2008).

In the current study, obstructive uropathy is responsible for 10.7% of ESRD on HD. From a research work in Arab world, FAISSAL and Al-Khader, 2005, found that, in many Arab countries, obstructive uropathy constitutes a major cause (40%) of ESRD. The two most common underlying causes of obstructive uropathy are renal calculi and schistosomiasis, El-Minia in Governorate obstructiveuropathy is blamed for 12% of cases of ESRD (El Minshawy, 2011). This may be due to hot weather and loss of water due to excessive sweating and concentrated urine.

Chronic pyelonephritis accounts for 5% of ESRD in El-Minia Governorate (Elminshawy 2011), but in our study it accounts 6.6% and in US it accounts 0.8% (USRDS, 2012) which reflects the high prevalence of bacterial, viral and parasitic infections such as schistosomiasis in our locality. In the US, according to the **USRDS data, 2012**, analgesic nephropathy was seen in only 0.2% of patients while it was2.9% in the current study; this reflects awareness of the people themselves in the US about the risk of excessive intake of analgesics. Another important cause is the widespread use of herbal medicines, in our locality, whose benefits and/or toxicity profiles have not been verified. These are compounded by the major problem of buying virtually any drug from the pharmacy without a doctor's prescription. Although bylaws exist against this practice, they are not enforced properly.

In the current study, polycystic kidney accounted for 3.7% of causes of ESRD, congenital kidney diseases occur in 3.3 per 1000 births (80% of which are due to hydronephrosis) (FAISSAL and Al-Khader, 2005). Polycystic kidney disease can be prevented through genetic counseling and premarital screening.

Hypertensionmore prevalent in urban areas (32.1%) than rural areas (31.7%), ESRD due to diabetic nephropathy was higher in urban (25.6%) than in rural areas (21.1%), while obstructive uropathy caused by schistosomiasis and renal stones was higher in rural (11.9%) than in urban areas (8.9%). The causes of ESRD showed no significant differences between rural and urban areas due tourbanization and migration.

In this study the prevalence of hepatitis C was found to be 55 % among patients with ESRD on HD. The high prevalence of hepatitis C is due to high rate of blood transfusion in dialysis units and it was estimated to be 52% in Egypt(Afify , 2008), 54.4 % in Syriawhich was reported byMoukeh *et al.*, 2009, 21 % in Jordan as documented by Batieha *et al.*, 2007, 18.9 % in Saudi Arabia (Hussein *et al.*, 2007), and31.4 % - 51 % in Turkey (Kaya, 2008). The high incidence of HCV can be associated with glomerulonephritis, only 2.6% of patients undergone to renal biopsy in our study, that is why (GN) may be the underlying cause of ESRD in cases of unknown cause.

In evaluation of our result, we didn't find a proper registry system if any. Also, we could not find clear detected data in registry; which is poor in different dialysis units; regarding the care which is given to ESRD patients on HD. No results of biopsies done for patients were found. Also, we could not find registry of laboratory results in most of dialysis units except in Tanta university hospital unit, Al Mogamaa hospital unit and El-Mahalla El-Kobra units, and no echo-cardio graphic examination was recorded for any of the patients.

In conclusion

in Al-Gharbiyah Governorate, the most common cause of ESRD is hypertensive renal disease followed by diabetic nephropathy then unknown cause was the 3rd cause of ESRD. Most of hemodialysis units in Al-

Gharbiyah Governorate don't have a proper registry which could be an interfering factor accounting for the high rate oh ESRD of unknown cause. We recommendto initiatea registry systemin the units of hemodialysis in Al-Gharbiyah Governorate. This will help proper follow up of patients, proper research works and proper preventive programs of ESRD. Also, we recommend proper campaign activities for detection and treatment of diabetes mellitus and hypertension in the community which may be of value in early detection of hypertensive and diabetic patients, which are usually diagnosed late after complications are there.

Corresponding author

Abd El Raouf, Y. M

Internal Medicine Department, Faculty of Medicine, Tanta University, Egypt Email: <u>masyasser@yahoo.com</u>

References;

- Abboud, H., andHenrich, W. L., (2010): Clinical practice. Stage IV chronic kidney disease. N Engl J Med; 362:56-65.
- Afifi, A., (2008): Annual reports of the Egyptian renal registry; 1996-2008, <u>http://www.esnonline.net</u>. Accessed on 12/6/2015
- Agarwal, S. K.; Dash, S. C. andIrshad, M., et al., (2005): Prevalence of chronic renal failure in adults. Nephrol Dial Transplant; 20(8):1638-42.
- 4. Alam, A. and Perron, R. D., (2010): Management of ESRD in patients with autosomal dominant polycystic kidney disease. Adv chronic kidney dis.;17(2):162-72.
- 5. Al-Sayyari, A. A. andShaheen, F. A., (2011): End Stage Chronic Kidney disease. A rapidly changing scene. Saudi Med J; 32:339-46.
- 6. Barsoum, R. S., (2002): End-stage renal disease in the developing world. Artif. Orangs; 26:73.
- 7. Batieha, A.; Abdallah, S. and Maghaireh, M., *et al.* (2007): Epidemiology and cost of haemodialysis in Jordan. East Mediterr Health J; 13(3):654-63.
- Couchoud, C.; Lassalle, M. and Stengel, B., *et al.* (2009): Renal Epidemiology and Information Network: 2007 annual report. NephrolTher; 5 (Suppl 1):S3-S11.
- El-Amin, A.; Obeid, W. and Abu-Aisha, H., (2010): Renal Replacement Therapy in Sudan, 2009. Arab J Nephrol Transpl;3:31-36.
- El-Minshawy, O., (2011): End-stage renal disease in the El-Minia Governorate, Upper Egypt: An Epidemiological Study. Saudi J Kidney Dis Transpl; 22:1048-54.
- 11. El-Reshaid, W.; El-Reshaid, K. and Kapoor, M., *et al.*(2005): Chronic renal disease in Kuwaiti nationals: a prospective study during the past 4 years. Ren Fail; 27(2):227-33.

- 12. Faissal, A. M. and Al-Khader, A.A., (2005): Preventive strategies of renal failure in the Arab world. Kidney International; 68: S37–S40.
- 13. Gullion, C. M.; Keith, D. S. and Nichols, G. A., *et al.* (2006): Impact of comorbidities on mortality in managed care patients with CKD. Am J Kidney Dis; 48:212–220.
- 14. Hussein, M. M.; Mooij, J. M. and Hegazy, M. S., *et al.*(2007): The impact of polymerase chain reaction assays for the detection of hepatitis C virus infection in a hemodialysis unit. Saudi J Kidney Dis Transpl; 18(1):107-13.
- 15. Kaya, S., (2008): Treatment of chronic hepatitis C virus infection in hemodialysis patients. Mikrobiyol Bul; 42(3):525-34
- 16. KDIGO. (2013): KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Supp; 3(1):1-150).
- 17. KDOQI. (2007): Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease update of hemoglobin target. Am J Kidney Dis; 50:471-530.
- 18. Kimmel, P. L. and Peterson, R. A., (2005): Depression in end-stage renal disease patients treated with hemodialysis: tools, correlates, outcomes, and needs. Semin Dia.; 18:91–97.
- 19. Malekmakan, L.; Haghpanah, S. and Pakfetrat, M., *et al.* (2009): Causes of chronic renal failure among Iranian hemodialysis patients. Saudi J Kidney Dis Transpl; 20:501-4.
- Mihatsch, M. J.; Khanlari, B. and Brunner, F. P., (2006): "Obituary to analgesic nephropathy. An autopsy study". Nephrol. Dial Transplant; 21(11): 3139.
- Moukeh, G.; Yacoub, R. and Fahdi, F., *et al.* (2009): Epidemiology of hemodialysis patients in Aleppo city. Saudi J Kidney Dis Transpl; 20(1):140-6.
- 22. Naicker, S., (2009): End-stage renal disease in sub-Saharan Africa. Ethn Dis; 19 (Suppl 1): 13-5.
- 23. National Kidney Foundation. (2002): K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification . American Journal of Kidney Disease; 39(2):S46-S75.
- 24. Pérez-Oliva, J. F., (2009): Current status of renal replacement therapy in Cuba 2006. Ethn Dis; 19 (1 Suppl 1):S1-10-2.
- 25. Shaheen, F. A. and Al-Khader AA. (2005): Epidemiology and causes of end stage renal disease (ESRD). Saudi J Kidney Dis Transpl; 16(3):277-81.
- 26. Shigidi, M. M.;Ramachandiran, G. andRashed, A. H., *et al.*(2009): Demographic data and hemodialysis population dynamics in Qatar: A

five year survey. Saudi J Kidney Dis Transpl; 20(3): 493-500.

- 27. Soliman, A. R.;Fathy, A. andRoshd, D., (2012): The growing burden of End Stage Renal disease in Egypt. Ren Fail; 34(4):425-8.
- Steenkamp, R.;Castledine, C.;Feest, T. and Fogarty, D.,UK Renal Registry 13th Annual Report(2011): Chapter 2: UK RRT prevalence in 2009: national and centre-specific analyses. Nephron ClinPract; 119 (Suppl 2):c27-52.
- 29. Udayaraj, U.;Tomson, C. R. andGilg, J., *et al.* (2009): UK Renal Registry 11th Annual Report (December 2008): Chapter 6 Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland: national and centre-specific

analyses. Nephron ClinPract; 111 (Suppl 1):c97-111.

- UK Renal Registry, (2009): The 12th annual report [Internet]. Bristol: UK renal Registry; p. 351.
- 31. US Renal Data System. USRDS 2013 Annual Data Report, (2013): Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
- Yao, Q.; Zhang, W. and Qian, J., (2009): Dialysis status in China: a report from the Shanghai Dialysis Registry (2000-2005). Ethn Dis; 19 (Suppl 1):23-6.

Appendix 1

Modified Form Of Egyptian Society Of Nephrology Dialysis patient Questionnaire2009

Center\Hospital:	Obtained by:
Name Of Patient :	Age: SEX:
Occupation:	
Area of residence:	
Family history of ESRDS:	If+ve ,The cause is:
Educational level:	
Habits:	
BMI :	
HCV: COPD:	LVF: EF:

Etiology of Renal Failure

Reflux nephropathy& chronic pylonephritis: Chronic glomerulonephrities: Diabetic nephropathy: Hypertensive disease of the kidney: Obstructive uropathy due to schistomasis: Renal affection with schistosomal liver fibrosis: Obstructive uropathy (other than schistosomiasis): Gouty nephropathy: Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology: Result of renal biopsy if done at any stage of the disease:	
Diabetic nephropathy: Hypertensive disease of the kidney: Obstructive uropathy due to schistomasis: Renal affection with schistosomal liver fibrosis: Obstructive uropathy (other than schistosomiasis): Gouty nephropathy: Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Reflux nephropathy& chronic pylonephritis:
Hypertensive disease of the kidney: Obstructive uropathy due to schistomasis: Renal affection with schistosomal liver fibrosis: Obstructive uropathy (other than schistosomiasis): Gouty nephropathy: Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Chronic glomerulonephrities:
Obstructive uropathy due to schistomasis: Renal affection with schistosomal liver fibrosis: Obstructive uropathy (other than schistosomiasis): Gouty nephropathy: Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Diabetic nephropathy:
Renal affection with schistosomal liver fibrosis: Obstructive uropathy (other than schistosomiasis): Gouty nephropathy: Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Hypertensive disease of the kidney:
Obstructive uropathy (other than schistosomiasis): Gouty nephropathy: Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Obstructive uropathy due to schistomasis:
Gouty nephropathy: Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Renal affection with schistosomal liver fibrosis:
Complication of pregnancy: Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Obstructive uropathy (other than schistosomiasis):
Polycystic kidney of disease: Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Gouty nephropathy:
Other hereditary disease: Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Complication of pregnancy:
Lupus nephritis: Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Polycystic kidney of disease:
Renal affection secondary to other collagen diseases: Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Other hereditary disease:
Analgesic nephropathy: Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Lupus nephritis:
Renal amyloidosis: Other cause not mentioned in the list: Renal failure of unknown etiology:	Renal affection secondary to other collagen diseases:
Other cause not mentioned in the list: Renal failure of unknown etiology:	Analgesic nephropathy:
Renal failure of unknown etiology:	Renal amyloidosis:
	Other cause not mentioned in the list:
Result of renal bionsy if done at any stage of the disease.	Renal failure of unknown etiology:
Result of fende stopsy if done at any stage of the disease.	Result of renal biopsy if done at any stage of the disease:

8/12/2015